Trends in Immunotherapy

Article

Presepsin and Mortality Risk in Sepsis: A Valuable Tool for Predicting Patient Survival

Downloads

https://doi.org/10.54963/ti.v9i2.1097
Agustin Iskandar, Yeni Ayu Prihastuti, Indah Adhita Wulanda, Andrea Aprilia, & Muhammad Anshory. (2025). Presepsin and Mortality Risk in Sepsis: A Valuable Tool for Predicting Patient Survival. Trends in Immunotherapy, 9(2), 107–117. https://doi.org/10.54963/ti.v9i2.1097
Volume 9 Issue 2 ( 2025)
Copyright (c) 2025 Agustin Iskandar, Yeni Ayu Prihastuti, Indah Adhita Wulanda, Andrea Aprilia, Muhammad Anshory
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Agustin Iskandar

    Department of Clinical Pathology, Faculty of Medicine, Universitas Brawijaya, Dr. Saiful Anwar General Hospital, Malang 65111, Indonesia
  • Yeni Ayu Prihastuti

    Department of Clinical Pathology, Faculty of Medicine, Universitas Brawijaya, Dr. Saiful Anwar General Hospital, Malang 65111, Indonesia
  • Indah Adhita Wulanda

    Department of Clinical Pathology, Faculty of Medicine, Universitas Brawijaya, Dr. Saiful Anwar General Hospital, Malang 65111, Indonesia
  • Andrea Aprilia

    Department of Clinical Pathology, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta 14440, Indonesia
  • Muhammad Anshory

    Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Dr. Saiful Anwar General Hospital, Malang 65111, Indonesia

Received: 19 March 2025; Revised: 13 May 2025; Accepted: 29 May 2025; Published: 7 June 2025

Background: Early identification of high-risk sepsis patients is essential for timely intervention and improved survival. Prognostic biomarkers can support clinical decision-making by stratifying mortality risk and informing treatment choices. Sepsis remains a major global health challenge due to its complex management and high mortality rate. Presepsin, a soluble CD14 subtype (sCD14-ST), has emerged as a promising biomarker for sepsis prognosis, demonstrating superior predictive value compared to conventional markers like procalcitonin (PCT). This study aims to evaluate the prognostic significance of Presepsin in predicting mortality among sepsis patients. Methods: A prospective cohort study was conducted on 110 adult sepsis patients admitted to the ICU at Dr. Saiful Anwar Hospital, Malang, from November 2018 to October 2019. Patients were diagnosed using the Sepsis-3 criteria, and Presepsin levels were measured using the chemiluminescent immunoassay (CLIA) method. Survival analysis was performed using Kaplan-Meier curves, and hazard ratios (HR) were calculated through Cox regression. Results: The ROC analysis identified 17,085 pg/mL as the optimal Presepsin threshold for predicting mortality (AUC: 0.939, 95% CI: 0.897–0.982, p < 0.001). Patients with Presepsin levels ≥17,085 pg/mL had a significantly lower median survival (3 days) compared to those with lower levels (9 days) (HR 3.654, 95% CI: 1.978–6.752,  p < 0.001). Among patients with high Presepsin levels, 32 of 33 (96.9%) died, whereas only 28 of 77 (36.4%) patients with lower levels experienced mortality. Conclusion: Presepsin shows potential as a biomarker for identifying sepsis patients at increased risk of mortality. Its use may support early risk stratification and guide clinical decision-making in sepsis management.

Keywords:

Presepsin; Sepsis; Survival; Mortality Risk; Prediction

References

  1. World Health Organization (WHO). Sepsis: A Global Health Emergency; WHO Sepsis Report 2017; WHO: Geneva, Switzerland, 2017.
  2. Gaini, S.; Relster, M.M.; Pedersen, C.; et al. Prediction of 28-Days Mortality with Sequential Organ Failure Assessment (SOFA), Quick SOFA (qSOFA) and Systemic Inflammatory Response Syndrome (SIRS) – A Retrospective Study of Medical Patients with Acute Infectious Disease. Int. J. Infect. Dis. 2019, 78, 1–7. DOI: https://doi.org/10.1016/j.ijid.2018.09.020
  3. Singer, M.; Deutschman, C.S.; Seymour, C.W.; et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315, 801–810. DOI: https://doi.org/10.1001/jama.2016.0287
  4. Delano, M.J.; Ward, P.A. The Immune System’s Role in Sepsis Progression, Resolution, and Long-Term Outcome. Immunol. Rev. 2016, 274, 330–353. DOI: https://doi.org/10.1111/imr.12499
  5. Wacker, C.; Prkno, A.; Brunkhorst, F.M.; et al. Procalcitonin as a Diagnostic Marker for Sepsis: A Systematic Review and Meta-Analysis. Lancet Infect. Dis. 2013, 13, 426–435. DOI: https://doi.org/10.1016/S1473-3099(12)70323-7
  6. Tang, B.M.; Eslick, G.D.; Craig, J.C.; et al. Accuracy of Procalcitonin for Sepsis Diagnosis in Critically Ill Patients: Systematic Review and Meta-Analysis. Lancet Infect. Dis. 2007, 7, 210–217. DOI: https://doi.org/10.1016/S1473-3099(07)70052-X
  7. Ramana, K.V.; Pinnelli, V.B.; Kandi, S.; et al. Presepsin: A Novel and Potential Diagnostic Biomarker for Sepsis. Am. J. Med. Biol. Res. 2014, 2, 97–100.
  8. Zou, Q.; Wen, W.; Zhang, X.C. Presepsin as a Novel Sepsis Biomarker. World J. Emerg. Med. 2014, 5, 16–19. DOI: https://doi.org/10.5847/wjem.j.issn.1920-8642.2014.01.002
  9. Ko, R.E.; Kang, D.; Cho, J.; et al. Influence of Gender on Age-Associated In-Hospital Mortality in Patients with Sepsis and Septic Shock: A Prospective Nationwide Multicenter Cohort Study. Crit. Care 2023, 27, 229. DOI: https://doi.org/10.1186/s13054-023-04515-5
  10. Luethi, N.; Bailey, M.; Higgins, A.; et al. Gender Differences in Mortality and Quality of Life after Septic Shock: A Post-Hoc Analysis of the ARISE Study. J. Crit. Care 2020, 55, 177–183. DOI: https://doi.org/10.1016/j.jcrc.2019.11.002
  11. Baig, M.A.; Sheikh, S.; Hussain, E.; et al. Comparison of qSOFA and SOFA Score for Predicting Mortality in Severe Sepsis and Septic Shock Patients in the Emergency Department of a Low Middle Income Country. Turk. J. Emerg. Med. 2018, 18, 148–151. DOI: https://doi.org/10.1016/j.tjem.2018.08.002
  12. Nasa, P.; Juneja, D.; Singh, O. Severe Sepsis and Septic Shock in the Elderly: An Overview. World J. Crit. Care Med. 2012, 1, 23–30. DOI: https://doi.org/10.5492/wjccm.v1.i1.23
  13. Yang, Y.; Yang, K.S.; Hsann, Y.M.; et al. The Effect of Comorbidity and Age on Hospital Mortality and Length of Stay in Patients with Sepsis. J. Crit. Care 2010, 25, 398–405. DOI: https://doi.org/10.1016/j.jcrc.2009.09.001
  14. Silva, E.P.D.; Duarte, V.D.C.; Soares, M.M.; et al. Survival Analysis of Patients with Sepsis in Brazil. Rev. Soc. Bras. Med. Trop. 2019, 52, e20180121. DOI: https://doi.org/10.1590/0037-8682-0121-2018
  15. Koh, J.S.; Kim, Y.J.; Kang, D.H.; et al. Usefulness of Presepsin in Predicting the Prognosis of Patients with Sepsis or Septic Shock: A Retrospective Cohort Study. Yeungnam Univ. J. Med. 2021, 38, 318–325. DOI: https://doi.org/10.12701/yujm.2021.01018
  16. Behnes, M.; Bertsch, T.; Lepiorz, D.; et al. Diagnostic and Prognostic Utility of Soluble CD14 Subtype (Presepsin) for Severe Sepsis and Septic Shock during the First Week of Intensive Care Treatment. Crit. Care 2014, 18, 507. DOI: https://doi.org/10.1186/s13054-014-0507-z
  17. Pizzolato, E.; Ulla, M.; Galluzzo, C.; et al. Role of Presepsin for the Evaluation of Sepsis in the Emergency Department. Clin. Chem. Lab. Med. 2014, 52, 1395–1400. DOI: https://doi.org/10.1515/cclm-2014-0199
  18. Yang, H.S.; Hur, M.; Yi, A.; et al. Prognostic Value of Presepsin in Adult Patients with Sepsis: Systematic Review and Meta-Analysis. PLoS ONE 2018, 13, e0191486. DOI: https://doi.org/10.1371/journal.pone.0191486
  19. Masson, S.; Caironi, P.; Spanuth, E.; et al. Presepsin and Procalcitonin Levels for Mortality Prediction in Sepsis: Data from the ALBIOS Trial. Crit. Care 2014, 18, R6. DOI: https://doi.org/10.1186/cc13183
  20. Kim, H.; Hur, M.; Moon, H.W.; et al. Multi-Marker Approach Using Procalcitonin, Presepsin, Galectin-3, and Soluble Suppression of Tumorigenicity 2 for the Prediction of Mortality in Sepsis. Ann. Intensiv. Care 2017, 7, 27. DOI: https://doi.org/10.1186/s13613-017-0252-y
  21. Piccioni, A.; Santoro, M.C.; de Cunzo, T.; et al. Presepsin as Early Marker of Sepsis in Emergency Department: A Narrative Review. Medicina 2021, 57, 770. DOI: https://doi.org/10.3390/medicina57080770
  22. Baik, S.M.; Park, J.; Kim, T.Y.; et al. Validation of Presepsin Measurement for Mortality Prediction of Sepsis: A Preliminary Study. Acute Crit. Care 2022, 37, 527–532. DOI: https://doi.org/10.4266/acc.2022.00150
  23. de Moura, E.L.B.; Pereira, R.W. Crossing Age Boundaries: The Unifying Potential of Presepsin in Sepsis Diagnosis Across Diverse Age Groups. J. Clin. Med. 2024, 13, 7038. DOI: https://doi.org/10.3390/jcm13237038
  24. Giannakopoulos, K.; Hoffmann, U.; Ansari, U.; et al. The Use of Biomarkers in Sepsis: A Systematic Review. Curr. Pharm. Biotechnol. 2017, 18, 499–507. DOI: https://doi.org/10.2174/1389201018666170601080111
  25. Lee, S.; Song, J.; Park, D.W.; et al. Diagnostic and Prognostic Value of Presepsin and Procalcitonin in Non-Infectious Organ Failure, Sepsis, and Septic Shock: A Prospective Observational Study According to the Sepsis-3 Definitions. BMC Infect. Dis. 2022, 22, 8. DOI: https://doi.org/10.1186/s12879-021-07012-8